Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

41 recruiting

Showing 120 of 70 trials

Recruiting
Phase 3

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Coagulation Disorder
Takeda440 enrolled64 locationsNCT05156983
Recruiting
Phase 3

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.737 enrolled143 locationsNCT05254743
Recruiting

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

Hereditary Angioedema (HAE)
Takeda40 enrolled24 locationsNCT07251933
Recruiting

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Parkinson Disease
Michael J. Fox Foundation for Parkinson's Research4,500 enrolled50 locationsNCT04477785
Recruiting

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Pain
Boston Scientific Corporation4,800 enrolled118 locationsNCT01719055
Recruiting

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Parkinson's Disease
Boston Scientific Corporation1,500 enrolled84 locationsNCT02071134
Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 1Phase 2

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled32 locationsNCT04802759
Recruiting
Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
Phase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled109 locationsNCT06919965
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled393 locationsNCT07196748
Recruiting
Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled250 locationsNCT06852222
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 1Phase 2

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC235 enrolled59 locationsNCT05316155
Recruiting
Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled169 locationsNCT07438496
Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled191 locationsNCT04892173
Recruiting
Phase 3

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 2Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease
Janssen Research & Development, LLC1,092 enrolled363 locationsNCT07196722
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686